What is the latest approach to pulmonary cryptococcosis?

Journal of Respiratory Diseases

Volumn 25, Issue 5, 2004, Pages 188-199

  Casadevall, Arturo ^a,b  

^a Dept of Med/Microbiol/Immunol ^*  (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CRYPTOCOCCUS ANTIGEN; FLUCONAZOLE; FLUCYTOSINE; FUNGUS ANTIGEN; ITRACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIGEN DETECTION; BLOOD CULTURE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISSEMINATED DISEASE; DYSPNEA; FEVER; FUNGAL VIRULENCE; FUNGUS ISOLATION; HEMOPTYSIS; HUMAN; LUMBAR PUNCTURE; LUNG DISEASE; LUNG PARENCHYMA; PATHOGENESIS; REVIEW; SIDE EFFECT; SKIN DEFECT; SPUTUM ANALYSIS; SYMPTOMATOLOGY; THORAX RADIOGRAPHY;

EID: 2442419706     PISSN: 0194259X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Hajjeh RA, Conn LA, Stephens DS, et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis. 1999;179:449-454.
2. Salyer WR, Salyer DC, Baker RD. Primary complex of Cryptococcus and pulmonary lymph nodes. J Infect Dis. 1974;130:74-77.
3. Littman ML. Cryptococcosis: current status. Am J Med. 1968;45:922-932.
4. Goldman DL, Khine H, Abadi J, et al. Serologic evidence for Cryptococcus infection in early childhood. Pediatrics. 2001; 107:E66.
5. Abadi J, Pirofski L. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without HIV infection. J Infect Dis. 1999;180:915-919.
6. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 1999;37:3204-3209.
7. Goldman D, Lee SC, Casadevall A. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun. 1994;62:4755-4761.
8. Pirofski L, Casadevall A. The meaning of microbial exposure, infection, colonisation, and disease in clinical practice. Lancet Infect Dis. 2002; 2:628.
9. Casadevall A, Perfect JR. Cryptococcus neoformans. Washington, DC: American Society for Microbiology Press; 1998.
10. Sweeney DA, Caserta MT, Korones DN, et al. A ten-year-old boy with a pulmonary nodule secondary to Cryptococcus neoformans: case report and review of the literature. Pediatr Infect Dis J. 2003;22:1089-1093.
11. Fessel WJ. Cryptococcal meningitis after unusual exposures to birds. N Engl J Med. 1993 328:1354-1355.
12. Procknow JJ, Benfield JR, Rippon JW, et al. Cryptococcal hepatitis presenting as a surgical emergency. First isolation of Cryptococcus neoformans from point source in Chicago. JAMA. 1965;191:93-98.
13. Franzot SP, Salkin IF, Casadevall A. Cryptococcus neoformans var. grubli: separate variety status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol. 1999;37:838-840.
14. Sorrell TC. Cryptococcus neoformans variety gattii. Med Mycol. 2001;39:155-168.
15. Stephen C, Lester S, Black W, et al. Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can Vet J. 2002;43:792-794.
16. Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin Infect Dis. 2000;31:499-508.
17. Vilchez RA, Irish W, Lacomis J, et al. The clinical epidemiology of pulmonary cryptococcosis in non-AIDS patients at a tertiary care medical center. Medicine (Baltimore). 2001;80:308-312.
18. Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococcosis in patients without HIV infection. Chest. 1999;115:734-740.
19. Meighan JW. Pulmonary cryptococcosis mimicking carcinoma of the lung. Radiology. 1972;103:61-62.
20. Baird RW, Garfiled AS. Cavitation and rupture of a pulmonary cryptococcoma in an immunocompetent man. Am J Med. 1994;97:309-311.
21. Amundson DE. Cavitary pulmonary cryptococcosis complicating Churg-Strauss vasculitis. South Med J. 1992;85:700-702.
22. Salyer WR, Salyer DC. Pleural involvement in cryptococcosis. Chest. 1974;66:139-140.
23. Torre D, Martegani R, Speranza F, et al. Pulmonary cryptococcosis presenting as pneumothorax in a patient with AIDS. Clin Infect Dis. 1995;21:1524-1525.
24. Wong CM, Lim KH, Liam CK. Massive pleural effusions in cryptococcal meningitis. Postgrad Med J. 1999;75:297-298.
25. Cameron ML, Bartlett JA, Gallis HA, Waskin HA. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis. 1991;13:64-67.
26. Larsen RA, Bozette S, McCutchan JA, et al. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group. Ann Intern Med. 1989;111:125-128.
27. Currie BP, Freundlich LF, Soto MA, Casadevall A. False-negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture-positive cryptococcal meningitis. J Clin Microbiol. 1993;31:2519-2522.
28. Duperval R, Hermans PE, Brewer NS, Roberts GS. Cryptococcosis, with emphasis on 'the significance of isolation of Cryptococcus neoformans from the respiratory tract. Chest. 1977;72:13-19.
29. Goldman DL, Lee SC, Casadevall A. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun. 1995;63: 3448-3453.
30. Tynes B, Mason K, Jennings AE, Bennett JE. Variant forms of pulmonary cryptococcosis. Ann Intern Med. 1968;69:1117-1125.
31. Hammerman KJ, Powell KE, Christianson CS, et al. Pulmonary cryptococcosis: clinical forms and treatment. Am Rev Respir Dis. 1973; 108:1116-1123.
32. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:710-718.
33. Driver JA, Saunders CA, Heinze-Lacey B, Sugar AM. Cryptococcal pneumonia in AIDS: is cryptococcal meningitis preceded by clinically recognizable pneumonia? J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:168-171.
34. Kerkering TM, Duma RJ, Shadomy S. The evolution of pulmonary cryptococcosis. Ann Intern Med. 1981;94:611-616.
35. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococoal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999;28:291-296.
36. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001;33:690-699.
37. Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother. 1999;43: 169-171.
38. Van Duin D, Casadevall A, Nosanchuk JD. Melanization affects the susceptibility of Cryptococcus neoformans and Histoplasma capsulatum to amphotericin B and caspofungin. Antimicrob Agents Chemother. 2002;46:3394-3400.
39. Visnegarwala F, Graviss EA, Lacke CE, et al. Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin Infect Dis. 1998;27:1231-1237.
40. Vilchez RA, Unden P, Lacomis J, et al. Acute respiratory failure associated with pulmonary cryptococcosis in non-AIDS patients. Chest. 2001;119:1865-1869.